Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AtriCure nets $47.4mm with IPO

Executive Summary

AtriCure (develops surgical devices to create precise lesions in soft tissues) netted $47.4mm (including the overallotment) in its initial public offering of 4.15mm common shares priced at $12 each. The company originally filed in April with the intention of bringing in $57.5mm. It plans to trade on the Nasdaq under the symbol ATRC. Selling shareholders also offered 450k shares.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies